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1. Introduction 
Malignant gliomas are primary brain tumors, which are highly invasive but not known to 
metastasize outside the central nervous system (CNS). The median survival time of patients 
with glioma is only 6 months to 2 years depending on various patient, tumor and treatment 
parameters (Louis et al. 2007). The highly aggressive character of gliomas with glioblastoma 
multiforme (GBM) being the most aggressive subtype are characterized by their diffuse 
infiltration into the normal brain parenchyma and interaction with the extracellular matrix 
(ECM) components in the brain. Standard brain tumor therapies, which include surgery 
followed by chemotherapy and radiation are not effective in eradicating single glioma cells 
that migrated into the normal brain establishing new tumor foci. Glioma cells are locally 
invasive and when migrating through the ECM within several millimeters or centimeters 
from the main lesion they initiate recurrent tumors often distant to the primary lesion 
(Bolteus et al. 2001). The infiltrative path of glioma into the normal brain parenchyma 
involves the basement membrane of blood vessels and myelinated nerve fibers of white 
matter tracts (Rao 2003, Lefranc et al. 2005).  
The pattern of glioma cell invasion is related to the unique composition of the cerebral ECM 
microenvironment, which is remodeled during invasion by activated matrix 
metalloproteinases (MMPs) (reviewed by Rojiani et al. 2011). In addition, new ECM 
molecules are secreted and receptor adhesion molecules are expressed by glioma promoting 
the glioma cell-ECM interaction and signaling. Some of the secreted ECM molecules such as 
tenascin-C are known to be associated with cell motility and angiogenesis which are both 
essential for tumor development. Another important microenvironment component 
affecting glioma development was found to be mechanical force determined by ECM 
rigidity. More rigid ECM promotes glioma migration and proliferation and lower rigidity of 
ECM (similar to that of normal brain) would have an opposite effect (Ulrich et al. 2009). 
The recent sequencing data presented by the Cancer Genome Atlas Research Network 
(2008) revealed genomic abnormalities in GBM that relate to several signaling pathways 
such as Epidermal Growth Factor Receptor (EGFR) /Ras /PI3K known to be associated with 
ECM-related signaling (Ulrich et al. 2009). In addition, the recent integrated genomic 
analysis identified clinically relevant subtypes of GBM with its characteristic abnormalities 
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in platelet derived growth factor receptor A (PDGFRA), isocitrate dehydrogenase 1 (IDH1), 
neurofibromin 1 (NF1), and confirmed EGFR mutations across all newly defined subtypes of 
GBM such as classical, proneural, neural and mesenchymal (Verhaak et al. 2010). The most 
recent studies by Holland (2011) in PDGF-driven mouse models of proneural GBMs with a 
focus on the biology, therapeutic response and the complexity of the microenvironment 
showed that some of the genes found in mice are predictive of the survival of patients with 
this proneural subtype of GBM. Interestingly, many of these genes are rather expressed in 
the stroma of the tumor than by the tumor cells themselves.  
In this chapter, the most recent information pertaining to the glioma extracellular 
microenvironment and the possible biological targets within ECM for anti-glioma therapy 
will be reviewed.  
2. Extracellular matrix molecules in the normal brain  
In the central nervous system (CNS) approximately only 15-25% of the CNS volume is taken 
up by the extracellular space, while the majority of the CNS volume consists of cellular 
elements such as neurons, glia, astrocytic processes and blood vessels (Sykova 2002, 
Quirico-Santos et al. 2010). The components found within the extracellular space include 
various ions, metabolites, neurohormones, peptides and ECM molecules produced by 
neurons and glia. The ECM environment of the normal brain contains high levels of space-
filling carbohydrate molecules unbound to proteins such as the large glycosaminoglycan 
(GAG) hyaluronan (HA). HA binds to specific cell surface receptors such as cluster 
determinant 44 (CD44) adhesion molecule and receptor for hyaluronate mediated motility 
(RHAMM) regulating properties of ECM and tissue, e.g., proliferation, adhesion, motility 
etc. Protein-bound carbohydrate molecules, which are present in the normal brain at high 
levels, include sulfated proteoglycans such as chondroitin sulfate proteoglycans (CSPGs) 
and heparan sulfate proteoglycans (HSPGs). In addition, fibrous proteins associated with 
the basement membranes of the brain’s vasculature include collagens, fibronectin, and 
laminin (Wiranowska and Plaas 2008). The levels of these fibrous proteins in the normal 
brain are low compared to the connective tissue outside the central nervous system (Bellail 
et al. 2004, Quirico-Santos et al. 2010). However, the ECM microenvironment of glioma 
differs from the normal brain and varies depending on the grade of glioma, e.g., with the 
highly aggressive GBM producing collagen, fibronectin or laminin (Mahesparan et al. 2003). 
Several classes of ECM molecules play an important role in the normal CNS development 
but have altered functions in glioma are reviewed below. 
The main classes of ECM components in the normal brain are GAG hyaluronan (HA), also 
called hyaluronic acid, and proteoglycans (PGs), which consist of a core protein attached to 
GAG chain. HA plays multiple roles in providing an organization of the pericellular matrix. 
There is a high diversity of PGs due to various core proteins, and variations in GAG side 
chains. Two classes of transmembrane PGs, glypicans and syndecans, which contain 
heparan sulphate (HS) side chains called HSPGs are found at high levels in the CNS.  
An important class of PGs are chondroitin sulfate PGs (CSPGs), which are expressed at high 
levels in the regions of the developing fetal brain and later in mature brain in astrocytes and 
neurons (Rao 2003, Quirico-Santos et al. 2010). CSPGs, and especially the subclass of 
lecticans, are one of the major families of HA binding matrix glycoproteins in the CNS. A 
second family of PGs that bind HA in the CNS are HA- and proteoglycan-link proteins 
(HAPLNs) also called "link proteins”, which bind both HA and lecticans. The PGs called 
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lecticans contain lectin and HA-binding domains and within that group there are molecules 
such as aggrecan, versican, neurocan, and brain enriched hyaluronic acid binding 
protein/brevican (BEHAB/brevican) that act as linkers to ECM components. They bind to 
HA as well as to cell-surface receptors regulating many processes within the CNS during 
development, e.g., cell motility, axonal navigation etc. (Sim et al. 2009). Some of these 
molecules such as versican are known to be produced by glial cells and neural stem cells 
(Abaskharoun et al. 2010). Another member of CSPGs is phosphocan, an astroglial 
proteoglycan that binds to neural cell adhesion molecules and tenascin-C. Neuroglial 
protein-2 (NG2), also a CSPG proteoglycan, which is known as a characteristic marker of 
oligodendrocyte progenitor cells and pericytes in developing vasculature, is expressed by 
many gliomas. The NG2 positive cells have been suggested to be the originating cells for 
glioma (Stallcup and Huang 2008).  
Tenascins (C and R), a family of glycoproteins exist in the ECM as assemblies of several 
subunits expressed in zones of proliferation, migration, and morphogenesis and are known 
to play an important role in the developing CNS. For example, tenascin-C was found highly 
expressed in the subventricular zone and essential for neural stem cell development 
(reviewed by Wiranowska and Plaas 2008). Galectins (Gal) , mannose- binding lectins, are 
glycan-binding proteins found inside and outside the cells. Gal-1 is highly represented in 
the CNS and takes part in the development of neural and non-neural networks and Gal-3 
interacts with other neural tissue derived glycoproteins and is expressed by astrocytes and 
endothelial cells (Quirico-Santos et al. 2010). The role of many ECM components of the 
normal brain described above, are altered dramatically in glioma.  
In the normal brain, the ECM complexes containing HA and PGs such as versican, brevican, 
neurocan, aggrecan, phosphacan and tenascin-C, tenascin-R, and link proteins form the 
ECM domains called perineuronal nets first described by Camillo Golgi in 1893. These 
perineuronal net aggregates enwrap the neuronal cell bodies and proximal dendrites of 
certain neurons and fill the space between neurons and glial processes. More recently, it was 
proposed that perineuronal nets within the brain are more heterogenous and include 
structures called “interstitial clefts” (Brightman 2002). As described by Brightman 
(Brightman 2002), interstitial clefts comprised of astrocytic walls, basal lamina and ECM 
molecules may vary in size , shape and content depending on the brain region. In addition, 
the size and the content of interstitial clefts was found to be different in the mature brain by 
being narrower with limited capacity for cell movement compared to that in the fetal brain. 
Here, in the fetal brain, the size and the content of interstitial clefts permit cell migration and 
outgrowth of neurites while in the mature brain cell migration in the interstitial clefts could 
only occur after enzymatic degradation of the ECM (Brightman 2002).  
2.1 Extracellular matrix in the brain as a cytokine and growth factor depot  
In the normal brain some regions are especially rich in ECM. These brain regions include 
subarachnoid space, supependymal packets, circumventricular organs (CVOs) supplied by 
fenestrated capillaries without blood-brain barrier (BBB), and perivascular space around 
arterioles and venules. These vessels are associated with stromal connective tissue space and 
lined by basal laminae containing heparan sulfate proteoglycans (HSPGs). HSPGs which are 
also components of ependymal, astroglial, and endothelial interfaces in the CNS (including 
interstitial clefts) have been suggested to serve as a storage site of growth factors and 
cytokines (Brightman and Kaya 2000). A large number of growth factors, for example, 
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insulin-like growth factor (IGF), transforming growth factor–beta (TGF-beta), hepatocyte 
growth factor (HGF) were found to bind to HSPG (Folkman 1998). A similar observation 
was made for certain cytokines (reviewed by Wiranowska and Plaas 2008). It was suggested 
by Mercier et al. (Mercier et al. 2003) that cytokines and growth factors secreted by cells of 
connective tissue may accumulate in the basal lamina, interact with ECM proteins and affect 
biological processes including cytogenesis of stem cells in the CNS.  
2.2 Extracellular matrix stem cell niche in the brain  
In the CNS, the ability of normal stem cells to self-renew and to differentiate into specific 
cell types is controlled by the microenvironment of a CNS area in which these cells reside 
and which is called niche. Similarly, in other tissues and organs, stem cells are found in the 
protective microenvironment of niches, which are composed of ECM molecules and various 
differentiated cell types that release regulatory factors and provide direct contact with stem 
cells maintaining their quiescence. The CNS microenvironment of the neural stem cells 
(NSC) niche is also called vascular niche, because stem cells concentrate near blood vessels. 
The NSC niche consists of several ECM components, and includes the basal lamina and 
endothelial cells of vasculature (Doetsch 2003). These mature, differentiated vascular 
endothelial cells have an intimate association with stem cells and play a regulatory role in 
the NSC niche through secreted soluble factors. These factors were shown to promote 
activation of Notch, a neural precursor receptor, resulting in self-renewal of neural stem 
cells (Shen et al. 2004). In addition, the basement membrane (also known as basal lamina) 
contributes to the microenvironment and provides a substrate for stem cells’ movement. The 
subventricular zone, a highly neurogenic area in the CNS, contains transmembrane HSPGs 
bound to the supependymal basal lamina located in proximity to the stem cells. As 
mentioned earlier (Section 2.1), HSPGs have the capacity to bind and to store a number of 
growth factors and cytokines thereby serving as a cytokine and growth factor depot. The 
growth factors and cytokines can diffuse quickly, and because of close proximity, they can 
reach high concentrations near the stem cells and regulate their development (Kearns et al. 
2003) . For example, EGF and basic fibroblast growth factor (bFGF) stored in the ECM of the 
subventricular zone can have a stimulatory effect on stem cells by enhancing their 
proliferation. The growth factors and cytokines can be stored in the ECM throughout life.  
As mentioned earlier, one of ECM molecules, tenascin-C, is highly expressed in the 
subventricular zone and essential for neural stem cell development (Wiranowska and Plaas 
2008). Tenascin-C plays a key role in the regulation of the developmental program of 
oligodendrocyte precursor cells (OPCs) and therefore confirming the importance of 
tenascin-C as an ECM component of the niche (Scadden 2006). Other ECM molecules, such 
as laminin and fibronectin, stimulate motility of stem/progenitor cells while CSPGs have an 
inhibitory effect (Kearns et al. 2003). It was also observed that upon activation of MMPs by 
proinflammatory cytokines, the neural progenitor cells were stimulated to migrate to the 
site of injury (Ben-Hur et al. 2006). In summary, many modulatory molecules were 
described within the ECM of the stem cell niche and, interestingly, many of them were 
found in glioma, but at higher levels than in the normal brain. In addition, not only the 
levels but also the functions of many of these molecules differ between the normal brain and 
glioma such as CSPGs, which are inhibitory for stem cells migration within the niche of the 
normal brain but stimulatory for glioma cell migration (Kearns et al. 2003, Sim et al. 2009). 
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3. Extracellular matrix in glioma 
3.1 Role of ECM and MMP molecules in vasculogenic mimicry in glioma: Historical 
perspective  
It was observed previously by Maniotis et al. (Maniotis et al. 1999) that blood vessels of 
highly aggressive tumors such as uveal melanoma originated from tumor cells, rather than 
from endothelial cells as it was originally expected. This phenomenon named vasculogenic 
mimicry (VM) was reported later also for other tumors including glioma (Yue and Chen 
2005). Although the mechanism of VM could not be explained at that time, many studies 
evaluated MMPs and ECM interactions in search for clues. It was suggested that several 
components of the tumor microenvironment may be contributing to the development of 
VM. For example, consideration was given to MMPs’ cleavage of laminin, VE-cadherin- 
promoted adherence of newly formed vascular channels to tumor cells, and 
dedifferentiation of tumor cells (Zhang et al. 2007). Three main factors were suspected to 
play a role in VM: 1) plasticity of malignant tumor cells, 2) remodeling of the ECM by MMPs 
secreted by tumor cells to obtain space for VM, and 3) the connection of newly formed VM 
channels with existing blood vessels to acquire blood from the host (Zhang et al. 2007). It 
was proposed by Maniotis et al. (Maniotis et al. 1999) that the level of the VM channel 
formation was directly proportional to the level of tumor aggressiveness and influenced by 
interstitial fluid pressure (IFP), a microenviromental factor known to affect angiogenesis. 
Tumors that proliferate rapidly have high IFP and compromised blood circulation. In 
addition, there is a limited blood supply from the host due to decreased endothelial cell 
sprouting and decreased formation of endothelium-lined blood vessels. Therefore, tumor 
cells that form VM channels obtain a sufficient blood supply to sustain tumor growth. It was 
observed that the blood vessels formed as a result of VM had a different structure than 
normal endothelial-lined blood vessels. VM channels were found to be lined by highly 
aggressive and poorly differentiated tumor cells that could degrade the base membrane of 
blood vessels by releasing proteases and migrate into the normal tissue. Recent data (Inoue 
et al. 2010) support this observation by showing that GBM cancer stem cells express MMP-
13 responsible for invasion and migration of these cells. 
Anti-vascular and anti-angiogenic therapies that used molecules such as angiostatin or 
endostatin that target endothelial cells, showed no effect on tumors with VM. To overcome 
the lack of understanding of the molecular mechanisms underlying VM, several in vitro 
studies were initiated in search of new therapeutic approaches based on the concept of ECM 
involvement in VM formation. For example, laminin was targeted in vitro showing that an 
anti-laminin antibody was able to inhibit VM channel formation by tumor cells (Sanz et al. 
2003). Other in vitro studies targeted and inhibited MMP-2 and MMP-9 involved in VM by 
using doxcyline (Zhang et al. 2007). Also, it was shown that the Cox-2 inhibitor, celecoxib, 
inhibited in vitro VM formation in a dose-dependent manner (Basu et al. 2005). Although, 
these results were only obtained in vitro, there may be a recent indirect in vivo confirmation. 
Interestingly, recent in vivo studies using a glioma mouse model, showed that non-steroidal 
anti-inflammatory drugs (NSAID) such as Cox-2 inhibitors suppress gliomagenesis (Fujita et 
al. 2011). Although the primary conclusion of this study was that gliomagenesis was 
suppressed due to inhibition of prostaglandin E2-dependent accumulation of myeloid 
derived suppressor cells in the tumor microenvironment, a secondary effect of Cox-2 
inhibitors on VM may be involved as addressed in section 6.2.2.  
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3.2 Microenvironment of glioma stem cell vascular niche: New theory of vascular 
mimicry  
Recently, a new concept of cancer progenitor cells, also known as cancer-initiating cells or 
cancer stem cells (CSCs), was proposed. These self-renewing, multipotent CSCs are highly 
tumorigenic and resistant to conventional therapies (Lakka and Rao 2008). Glioblastoma 
CSCs resemble the normal NSC and express the markers Nestin+/ CD133+ found in the 
neural stem cell population. Also, glioma CSCs, similar to NSCs, concentrate around blood 
vessels in the vascular niches with easy access to nutrients, signaling molecules, and the 
vasculature itself as a substrate for migration (Calabrese et al. 2007, Denysenko et al. 2010). 
However, CSCs differ from NSCs in their distribution in the brain and their capacity to 
proliferate. For example, the normal NSCs, which proliferate at a low rate are found only in 
specific CNS regions such as hippocampus and subventricular zone. In contrast, highly 
proliferative glioma CSCs can be found distributed across in all regions of cerebrum and 
cerebellum within the tumors. It was proposed that the main difference between the normal 
NSCs and glioma CSCs may be the way in which these cells are modulated by the 
microenvironment of the vasculature within the niche (Calabrese et al. 2007). The vascular 
niche in brain tumors is abnormal in such that it contributes to the propagation of CSCs 
thereby enhancing tumor growth. Furthermore, the endothelial cells from this abnormal 
vascular niche can interact with brain tumor CSCs, as shown in vitro, providing certain 
extracellular regulatory factors and maintaining the self-renewal capability and 
undifferentiated state of these cells (Calabrese et al. 2007). In that way the glioma 
vasculature establishes a microenvironment of the niche in which CSCs can transmit and 
receive signals from the ECM. For example, it was shown that upon stimulation of CSCs by 
ECM of the vascular niche, the CSCs can secrete vascular endothelial growth factor (VEGF) 
promoting angiogenesis and thereby enhancing tumor growth (Bao et al. 2006). In addition, 
the vascular niche was shown to interfere with radiation and chemotherapy by shielding the 
CSCs and contributing to the resistance to treatments (Denysenko et al. 2010). It was also 
suggested that the microenvironment of the niche may play a role in tumor initiation based 
on the observation that non-tumorigenic cell populations may become tumorigenic 
depending on a certain microenvironment (Rosen and Jordan 2009). Recent reports show 
that GBM stem cells have similar capabilities as the normal NSCs and undergo 
differentiation into endothelial cells forming the majority of new blood vessels in gliomas 
(El Hallani et al. 2010, Ricci-Vitiani et al. 2010, Wang et al. 2010). Blocking VEGF or silencing 
VEGF receptor 2 inhibits the maturation of tumor endothelial progenitors into endothelium 
but does not stop the differentiation of CSCs (CD133+ cells) into endothelial cells. However, 
silencing of Notch (neural precursor receptor as mentioned in section 2.2) blocks the 
transition of CSCs (CD133+ cells) into endothelial progenitors (Wang et al. 2010). Further 
studies of the microenvironmental components within the brain tumor vascular niche could 
lead to new therapeutic targets for treatments of glioma.  
3.3 Extracellular matrix and mechanical rigidity in glioma  
There are anatomic variations in stiffness in the normal brain parenchyma (Elkin et al. 2007) 
with basement membrane of blood vessels and the myelinated fiber tracts of white matter 
exhibiting a higher mechanical rigidity (Lefranc et al. 2005) and both serving as an 
infiltrative path for glioma invasion (Rao 2003, Ulrich et al. 2009, Kumar 2009). It was first 
observed in vitro that directed migration of fibroblasts occurs from soft to stiff areas of the 
ECM, a phenomenon named mechanotaxis (Lo et al. 2000). A similar observation was made 
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for glioblastoma where changes in ECM rigidity can both increase and decrease cell motility 
and the extent of the effect was cell–type dependent (Thomas and DiMilla 2000). It was 
found that high ECM stiffness enhanced the expression of contractility-mediating proteins 
such as Rho (Paszek et al. 2005). ECM components have been found to be the main 
regulators of cell motility in the brain. For example, previous studies showed a stimulatory 
effect of ECM proteins such as fibronectin, collagen, laminin and others on glioma cell 
migration (Mahesparan et al. 2003). Ulrich et al. (Ulrich et al. 2009) had shown that glioma 
cells cultured on fibronectin-coated polymeric ECM with varied but defined mechanical 
rigidity exhibited altered cell morphology and cytoskeletal organization. These authors 
showed that glioma cells cultured on softer substrates showed a decreased spreading area, 
disappearing stress fibers and focal adhesions. Interestingly, all evaluated glioma cell lines 
cultured on the softest substrates were rounded but viable with cortical rings of F-actin and 
punctuate vinculin-positive focal complexes, and with no indication of apoptosis (Ulrich et 
al. 2009). The rigidity of the soft substrates used in that study was comparable to the ECM 
rigidity of normal brain parenchyma while an increased stiffness was characteristic for 
glioma and its surrounding stroma.  
In addition, it was shown that increasing ECM rigidity resulted in increased cell spreading, 
motility and proliferation. It was suggested previously that glioma cells actively remodel 
their microenvironment changing it from normal brain ECM to rigid tumor-like ECM 
(Nakada et al. 2007). Therefore, it was suggested that glioma cells modify their ECM 
through proteolytic degradation of the normal brain matrix and secretion of new ECM 
components, thereby providing for a stiffer and more rigid microenvironment which in turn 
sends mechanobiological signals that support glioma cell invasion (Ulrich et al. 2009). This 
was observed previously also for invading breast cancer cells (Provenzano et al. 2008). By 
targeting either the signaling pathways for mechanotaxis or mechanical remodeling itself, 
new therapeutic approaches could be developed for the treatment of glioma which would 
affect glioma invasion and proliferation.  
3.4 Extracellular matrix molecules in glioma 
3.4.1 Glycosaminoglycan hyaluronan and CD44 adhesion molecule 
Glioma cells constitutively produce HA and its production is increased during cell 
proliferation (Wiranowska and Naidu 1994, Wiranowska et al. 2010) promoting glioma 
invasion (Park et al. 2008). HA is synthesized at the plasma membrane by HA-synthases and 
the synthesis can be enhanced by various growth factors, e.g., epidermal growth factor 
(Knudson and Knudson 1993) Interestingly, the content of HA in glioma resembles that of 
embryonic brain cells (Delpech et al. 1993). HA binds to the HA-binding proteins called 
hyaladherins which include the CD44 surface receptor. CD44 is a transmembrane 
glycoprotein expressed by many cell types and by glioma. CD44 serves as a surface receptor 
for ECM molecules such as HA and CSPGs (Ranuncolo et al. 2002).  
CD44 receptor is overexpressed in glioma cells in vitro (Wiranowska et al. 2000, Yu et al. 
2010) and found in vivo at the leading edge of glioma at the brain-tumor interface 
(Wiranowska et al. 2006). The HA-CD44 interaction and CD44 shedding from the cell 
surface were found to be associated with glioma cell motility, migration, and infiltration into 
the normal brain parenchyma (Annabi et al. 2005). These authors also described that CD44 
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After binding to the CD44 receptor, HA can be endocytosed, transported into lysosomes and 
degraded by hyaluronidases into small oligosaccharides shown to have glioma - stimulatory 
activity (Novak et al. 1999). It was previously reported that while small HA fragments were 
found in the tumor tissues, native HA of high molecular mass was found in the normal and 
benign tissue (Rooney et al. 1995). Both the high levels of full length polymeric HA and its 
low molecular weight degradation products, HA fragments, known as oligosaccharides 
support glioma growth (Novak et al. 1999). The HA oligosaccharides, e.g., hexamer 
oligoHA-6 (HA-6) or decamer oligoHA-10 (HA-10) are able to displace full length HA via 
competition for CD44 receptor binding. HA can be effectively displaced by HA 
decasaccharides, such as HA-10, but not by HA oligosaccharides that are shorter than  
10-mer (Tammi et al. 1998). It was observed that full length, large size HA had an anti-
angiogenic property, whereas smaller oligosaccharides after degradation (3-10 disaccharide 
units) were no longer anti-angiogenic (Deed et al. 1997). We found that small size 
oligosaccharide, decamer HA-10, exogenously added to the cell culture stimulated HA 
production by glioma cells (Wiranowska et al. 2010), as previously described for normal 
human fibroblasts (Luke and Prehm 1999). These authors found that displacement of 
nascent HA from the receptors by HA oligosaccharides led to stimulation of HA synthesis 
(Luke and Prehm 1999). Further studies of HA and the role of HA-CD44 interaction in 
glioma growth and invasiveness may provide new therapeutic targets for the treatment of 
glioma. Recent therapeutic approaches targeting HA-CD44 interaction are discussed in the 
Section 5.2.  
3.4.2 Chondroitin sulfate proteoglycans (CSPGs)  
CSPGs are expressed at elevated levels in the developing brain (as described in sections: 2 & 
2.2). In the normal brain, they are known for their inhibitory effect on stem cell migration 
(section 2.2). In glioma however, CSPGs are upregulated and stimulate glioma cell 
migration (Kearns et al. 2003, Sim et al. 2009). The two members of the CSPG subclass of 
lecticans (described in section 2) such as versican and BEHAB/brevican are expressed at a 
higher level in glioma than in the normal brain tissue. In addition, it was reported that the 
VO/VI versican isoform expressed by migratory glioma cells interacts with surface 
receptors e.g., EGFR activating the ERK signaling pathway involved in tumor promotion 
(Ricciardelli et al. 2009). In addition, versican and brevican can form complexes with 
mesenchymal matrix proteins found in the ECM of glioma, but not in the ECM of the 
normal brain (Sim et al. 2009). Gliomas of various grades, e.g., astrocytoma and GBM secrete 
high levels of BEHAB/brevican. The CSPG lectican has an N-terminal HA-binding domain 
that interacts with fibronectin, thereby further stimulating glioma progression (Viapiano 
and Matthews 2006). Several other ECM molecules such as HA, CD44, tenascin and 
transforming growth factor beta2 (TGFbeta2) also interact with versican and promote brain 
tumor cell invasion. Recently, the link proteins HAPLN4 and HAPLN2 were shown to be 
reduced in malignant gliomas and it was suggested that this reduction may be associated 
with matrix remodeling by glioma. Therefore, in contrast to the normal brain tissue where 
CSPGs lecticans associated to HAPLNs serve as inhibitors of cell motility, in glioma this 
stabilizing role of link proteins may be reduced or lost resulting in proinvasive activity of 
CSPGs in glioma (Sim et al. 2009).  
Another member of CSPGs family, neuroglial protein 2 (NG2), is also overexpressed in 
glioma (Schrappe et al. 1991, Wiranowska et al. 2006). NG2 was first found to be expressed 
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by oligodendrocyte progenitor cells (section 2). NG2 expressed by glioma cells has a strong 
association with ECM ligands such as collagen VI and cellular ligands such as CD44. It has 
been implicated in the invasive behavior of glioma and found to be expressed in vitro and in 
vivo by highly migratory glioma cells while not found in non migratory cells (Lin et al. 1996, 
Galli et al. 2004, Wiranowska et al. 2006, Stallcup and Huang 2008). NG2 is not only 
expressed by oligodendrocyte progenitor cells and glioma cells but also by pericytes, which 
are associated with microvasculature and may play a role in the development of glioma 
vasculature (Stallcup and Huang 2008). Therefore, NG2 may be considered as one of the 
main CSPGs involved in glioma progression.  
3.4.3 Vasculature-associated ECM molecules expressed by gliomas 
The basement membrane of the cerebral vasculature contains collagens (type IV and V), 
fibronectin, laminin, vitronectin and HSPGs such as glypicans and syndecans. Some HSPGs, 
e.g., syndecan-2 were reported to be increased in brain tumors (Theocharis et al. 2010). 
Laminin, collagen and fibronectin were also shown to be expressed by normal brain tissue 
bordering with glioma cells in spheroids (Knott et al. 1998). In addition, some of these 
molecules are also expressed by cells of highly aggressive gliomas. For example, it was 
found that fibronectin was expressed by GBM in vitro and in gliomesenchymal junctions in 
tumors and their blood vessels (Rao 2003). Another molecule, vitronectin, was found to be 
expressed in late stage GBM while it was absent in normal brain and early stage of glioma 
(Yamamoto et al. 1994). Laminins, which were found in blood vessels and in the glial 
limitants externa in glioma, were also shown to be expressed by human glioma cells positive 
for glial fibrillary astrocytic protein (GFAP) (Tysnes et al. 1999). An active site on laminin 
which was capable of binding to CD44 was identified (Hibino et al. 2004). In addition, 
Ljubimova et al. (Ljubimova et al. 2004) found that highly invasive GBMs overexpressed 
laminin-8, a member of the subset of laminins characterized by containing the alpha4 chain. 
Moreover, these authors also found that laminin-8 not only facilitated tumor invasion in 
vitro, but was involved in tumor regrowth after completion of a therapy. On the contrary, a 
different isoform, laminin-9, was found in lower grade gliomas, astrocytomas, and at low 
levels in benign brain tumors and in normal brain tissue. Therefore, many of these ECM 
molecules originally known to be associated with vasculature and now found at various 
levels expressed by glioma cells could be considered as biomarkers of glioma progression.  
Tenascin –C , a proteoglycan synthesized by glial and neural crest cells is highly expressed 
in the subventricular zone and essential for the development of neural stem cells (as 
described in sections 2 & 2.2 ). Tenascin-C, which is believed to be produced by endothelial 
cells, was found around blood vessels in astrocytoma and its expression correlated with 
angiogenesis and tumor progression from grade II to grade III (Zagzag et al. 1995, Quirico-
Santos et al. 2010). Tenascin-C was found overexpressed in invasive glioma both in vitro and 
in vivo (Mahesparan et al. 2003) thus confirming its significance as an ECM molecule in 
glioma pathology. Also, galectins are upregulated in glioma and shown to be involved in 
glioma cell migration and angiogenesis. While high levels of Gal-1 are correlated with 
aggressiveness of many tumors, the expression of Gal-3 by astrocytes and endothelial cells 
can be used diagnostically to differentiate GBM from other, less malignant types of glioma 
(Quirico-Santos et al. 2010). The schematic representation of ECM glioma microenvironment 
and the summary of representative ECM molecules and their functional significance are 
shown in Figure 1 and Table1. 
www.intechopen.com
 




Fig. 1. Schematic representation of the extracellular matrix (ECM) microenvironment of 
invasive glioma with necrotic centers and associated brain parenchyma. Hyaluronic acid 
(HA), a long space-filling molecule composed of a carbohydrate chain is shown either 
unbound or bound to proteoglycans (PGs) via link proteins (LPs) or bound to CD44 
receptor. Also shown are two glioma associated ECM molecules (both chondroitin sulfate 
proteoglycans): brain enriched hyaluronic acid binding protein/brevican 
(BEHAB/brevican) and neuroglial protein-2 (NG2) with the latter expressed by glioma cells 
and pericytes of blood vessels. In addition, glycoprotein tenascin-C, and matrix 
metalloproteinases (MMPs) are shown. Blood vessels (BV) shown in the glioma and the 
associated brain parenchyma contain fibrous proteins such as collagens, laminins etc. and 
heparan sulfate proteoglycans (HSPGs) associated with the BV basement membrane.  
4. Proteases, Matrix Metalloproteinases (MMPs), Their Inhibitors (TIMPS) and 
remodeling of ECM in glioma 
Matrix Metalloproteinases (MMPs) are a class of enzymes known to be involved in normal 
tissue remodeling, but also produced by glioma cells (Wiranowska et al. 2000) and involved 
in modification of glioma ECM. In the past, MMPs were considered a potential target for 
anti-cancer therapies. The result of ECM degradation by MMPs is the release and diffusion 
of cytokines and growth factors stored in the ECM with subsequent further activation of 
MMPs by these factors (Wiranowska and Plaas 2008). Since upregulation of MMPs was 
traditionally associated with inflammation and cancer progression, MMPs were considered 
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a logical target for anti-cancer therapy. Supporting evidence was generated using transgenic 
mouse models overexpressing MMPs (Ha et al. 2001). 
 
 
Table 1. ECM molecules and their functional significance 
4.1 Proteases in glioma 
The local infiltration of neoplastic cells into healthy CNS parenchyma is the hallmark of 
gliomas. In this context it is relevant to note that the brain extracellular matrix differs in its 
composition from other such matrices and that glioma cells have the ability to exploit this 
environment for invasion. Glioma cells aggressively disseminate as single cells through this 
unique ECM of the central nervous system. They infiltrate along the periphery of blood 
vessels or along the longitudinal white matter tracts utilizing different proteolytic enzymes, 
to achieve their goal of both invasion and metastasis. Serine, cysteine and 
metalloproteinases are employed to breakdown connective tissue barriers, induce 
angiogenesis and penetrate normal brain tissue thereby achieving the invasive phenotype 
(reviewed by Rao 2003). The urokinase plasminogen activator (uPA)/plasmin system of the 
serine protease family have been shown to be up-regulated in gliomas (Lakka and Rao 2008) 
and high uPA levels are associated with poor prognosis. Cathepsin B is a lysosomal cysteine 
protease shown to be secreted at increased levels in gliomas, with expression being 
significantly higher in glioblastoma than in low-grade glioma and normal brain (Rao 2003, 
Lakka and Rao 2008).  
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The third and the most widely studied protease system implicated in gliomas are the matrix 
metalloproteinases (MMPs). MMPs are a diverse family of endopeptidases that utilize zinc 
at their active site and encompass a broad spectrum of substrates. Common structural 
features of MMPs include a signal peptide, a catalytic domain which harbors the conserved 
zinc-binding site and a hemopexin-like domain. The proteolytic activity of MMPs affects 
diverse cellular functions such as cell proliferation, adhesion, migration, angiogenesis, bone 
development, wound healing and mammary involution, among others, by virtue of 
cleavage of ECM constituents, pro-growth factors, growth factor receptors and cell adhesion 
molecules. Within the tumor microenvironment, MMPs have been well documented to play 
a critical role in metastasis and angiogenesis (Kessenbrock et al. 2010). 
The family of Metzincin proteinases to which the MMPs belong also includes ADAM (a 
disintegrin and metalloproteinase) and ADAMTS (a disintegrin and metalloproteinase with 
thrombospondin motifs). The ADAMs are mostly cell associated, and responsible for 
cleavage of other proteins like amyloid precursor protein and Notch and hence are also 
called “sheddases”. On the other hand the ADAMTS are secreted (Murphy 2008). The role of 
ADAMs family members in nervous system development has been documented (Yang et al. 
2006).Though these two subfamilies have not been extensively studied in glioma, there is 
some documentation of their role in these tumors. In this context, it has been shown that 
ADAM 8 and 19 are overexpressed in glioma correlating with invasion. ADAMTS 4 and 5 
cleave brevican, a component of the ECM in the normal brain and have been shown to be 
upregulated in glioma cells (Rivera et al. 2010). 
4.2 MMPs and their inhibitors (TIMPs) in glioma 
MMPs span a wide range of subtypes within this family of endopeptidases that utilize zinc 
at their active site and interact with different targets. The proteolytic activity of MMPs 
affects diverse cellular functions as mentioned above, particularly impacting cell 
proliferation, adhesion, migration and angiogenesis. Thus they are important effectors of 
tissue remodeling, acting at various levels. The human MMP family comprises of over 23 
members and cleaves every component of the ECM. They are classified as follows: 
1. The archetypal MMPs: these include the collagenases i.e. MMP-1, MMP-8 and MMP-13; 
Stromelysins include MMP-3, MMP-10, MMP-11; Other archetypal MMPs e.g. the 
metalloelastase i.e MMP-12, also includes MMP-12, MMP-19, MMP-20 and MMP-27 
2. Matrilysins include MMP-7 and MMP-26 
3. Gelatinases include MMP-2 and MMP-9 
4. Membran-type (MT)-MMPs include MMP-14, MMP-15, MMP-16, MMP-17, MMP-24 
and MMP-25 A subgroup of glycosylphosphatidylinositol (GPI) MT-MMP includes 
MMP-17 and MMP-25. 
5. Type II transmembrane MMPs include MMP-23A and MMP-23B-identical proteins 
encoded by distinct genes. 
The MT-MMPs are covalently linked to the cell surface, however secreted ones can also 
attach to the cell membrane by either binding to integrins or to CD44. MMPs are produced 
in cells as zymogens where cysteine from the pro-domain is bound to zinc at the catalytic 
site and require proteolytic cleavage for activation. Activation of MMPs often requires 
cleavage by other MMPs, or serine proteases outside the cell. However some, including the 
membrane-type MMPs, are activated intracellularly (Egeblad and Werb 2002). Besides 
activation of pro-enzymes, MMP activity is also regulated by gene expression, 
compartmentalization and inhibition of active enzymes by their specific tissue inhibitors. 
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Tissue inhibitors of metalloproteinases (TIMPs) are specific endogenous inhibitors of MMPs 
that have been correlated both positively and negatively in glioma invasion. 
4.2.1 MMPs in glioma 
MMP up-regulation has been implicated in several broad disease categories including 
inflammation, vascular pathologies, and cancer. Analysis of MMP expression in cancer 
patients show strong correlation between increased expression of many MMPs and tumor 
progression in a wide range of malignancies including gliomas. Within the tumor, MMPs 
are secreted by tumor cells, as well as by stromal cells of the tumor (Rojiani et al. 2010). It 
appears that tumor cells produce a potent factor called extracellular matrix 
metalloproteinase inducer (EMMPRIN) a cell surface glycoprotein of the immunoglobulin 
superfamily. EMMRPIN stimulates MMP expression in stromal cells and also in tumor cells 
(Jodele et al. 2006). 
Several studies have documented overexpression of MMPs in gliomas compared to normal 
brain tissue. However the MMPs involved in gliomas have almost exclusively been the 
gelatinases MMP-2 and MMP-9 (reviewed by Rao 2003).  
The glioma vasculature as well as infiltrating inflammatory cells, which form a portion of 
the glioma mass have been implicated in MMP expression (VanMeter et al. 2001). Strong 
gelatinase expression correlates with tumor grade (Forsyth et al. 1999, Wang et al. 2003). 
Intracranial implantation of glioblastoma cells in nude mice resulted in increased levels of 
MMP-9 during growth (Sawaya et al. 1998, Chintala et al. 1999). Raithatha et al. (Raithatha et 
al. 2000) carried out an RNA and protein localization study for gelatinases in a set of human 
gliomas with varied malignancy. They found that MMP-2 expression was most prominent 
in tumor cells whereas MMP-9 expression was seen in tumor cell but was more strongly 
expressed in the vasculature. Nakagawa et al. (Nakagawa et al. 1994) reported increased 
MMP-9 levels in blood vessels at proliferating margins. Recently Zhang et al. (Zhang et al. 
2009) showed that knockdown of Akt2 resulted in decreased MMP-9 expression with 
concomitant decrease in glioma invasion in vitro and in vivo. It should be pointed out that 
EMMPRIN levels have been shown to increase in glioma and correlate with tumor grade 
(Sameshima et al. 2000). EMMPRIN has also been shown to increase hyaluronan and co-
localizes with its receptor CD44 (Toole and Slomiany 2008). Given that Hyaluronan and 
CD44 are important players in the CNS and in gliomas (see section 3.4.1) EMMPRIN may 
play a significant role in glioma invasion. 
In vitro studies also manifest a strong correlation between the expression of gelatinases and 
glioma cell invasion (reviewed by Bellail et al. 2004). Using matrigel assay, it was shown that 
the most invasive GBM cell line produced the highest level of gelatinases (Uhm et al. 1996, 
Abe et al. 1994). Besides the gelatinases, there are a number of studies documenting the role 
of MT1-MMP as well as reports of other MMPs involved in gliomas. Lampert et al. (Lampert 
et al. 1998) found increased levels of gelatinases as well as MT1-MMP and MT2-MMP in 
brain tumors. Yamamoto et al. (Yamamoto et al. 1996) found that increased MT1-MMP 
expression is associated with the expression of activated form of MMP-2 which in turn 
correlated with malignant glioma progression in vivo. Overexpression of MT1-MMP in 
glioma cell lines leads to activation of pro-MMP-2 (Nakada et al. 2001, Deryugina et al. 
1997). Additionally, other studies show that MT1-MMP is increased in glioma-associated 
microglia and that glioma-released factors trigger this expression by microglia. The MT1-
MMP then activates glioma-derived proMMP-2 and promotes glioma expansion (Markovic 
et al. 2009). The known classical function of MT1-MMP is activation of proMMP-2 in 
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conjunction with TIMP-2. A complex of MT1-MMP and TIMP-2 interacts with proMMP-2 
thus resulting in cleavage of the pro-domain from MMP-2 (Murphy et al. 1999). Hence, it is 
not surprising that many studies on glioma define activation of proMMP-2. 
The gelatinases MMP-2 and MMP-9 as well as the membrane-type protease MT1-MMP have 
been well documented to play pivotal roles in invasion and angiogenesis (Handsley and 
Edwards 2005). Vascular basement membrane components are well recognized substrates of 
MMP-2 and MMP-9. MMP-9 is a known component of the angiogenic switch regulating the 
bioavailability of VEGF (Bergers et al. 2000). MMP-2 expression has been correlated with the 
degree of vascularization of tumor nodules (Fang et al. 2000). MT1-MMP deficient mice 
have provided convincing evidence for its role in angiogenesis (reviewed by Handsley and 
Edwards 2005). These same MMPs are found at the invasive front of the tumor. Invadopodia 
are actin-rich protrusions of tumor cells with proteolytic activity. The gelatinases and the 
MT1-MMP localize to or become activated at the invadopodia (Stylli et al. 2008). 
Within the realm of glioma angiogenesis, the gelatinases remain crucial. MMP-2 and MMP-9 
showed positive correlation with glioma invasion and angiogenesis (Wang et al. 2003). In a 
mouse model, glioma growth required host MMP-2 to support angiogenesis (Takahashi et 
al. 2002). Small interferring RNA (siRNA)-mediated targeting of MMP-9 inhibits glioma 
angiogenesis in in vitro and in vivo models (Lakka et al. 2005). Hypoxia-inducible factor-1 α 
(HIF1α) was shown to induce recruitment of CD45+ cells amongst other cellular 
components, in a murine glioblastoma model. MMP-9 activity of these bone marrow 
derived CD45+ cells was essential and sufficient to initiate angiogenesis by increasing VEGF 
bioavailability (Du et al. 2008). 
With regard to other MMPs, Lettau et al. (Lettau et al. 2010) have found that MMP-19 is 
strongly expressed in astroglial tumors and is also responsible for the invasion of glioma 
cells in vitro. In a study using the glioma cell line U251, Deng et al. (Deng et al. 2010) found 
that MMP-26 promoted cell invasion in vitro and in vivo. Stojic et al. (Stojic et al. 2008) have 
shown enhanced expression of MMP-1, MMP-11 and MMP-19 in glioblastoma multiforme 
in comparison to low grade astrocytomas and normal brain. Tenascin-C is an ECM protein 
of the brain parenchyma and its synthesis is known to be up-regulated in glioma. MMP-12 
was implicated in the invasion of glioma cell lines using tenascin-C in a three-dimensional 
matrix model (Sarkar et al. 2006).  
Hence, it appears that MMPs play a pivotal role in glioma aggressiveness which would 
appear to make them potential targets for therapy. However, it should be pointed out that 
MMPs, by virtue of their degradation capacity also generate endogenous angiogenesis 
inhibitors. Proteolytic cleavage of plasminogen by several MMPs generates angiostatin and 
endostatin is generated from the C-terminal fragment of collagen type XVIII. MMP-9 is 
involved in the release of Tumstatin, another inhibitor of angiogenesis. MMPs as potential 
targets are further discussed below. 
4.2.2 Tissue Inhibitors of Matrix Metalloproteinases (TIMPS) in glioma 
As mentioned above, MMP regulation occurs at four different levels i.e. transcription, 
zymogen activation, compartmentalization and natural endogenous inhibition. Inhibition by 
α2-macroglobulin and tissue inhibitors of metalloproteinases (TIMPs) occurs in the liquid 
phase and in tissues, respectively (Nagase et al. 1999, Brew et al. 2000). Although TIMPs have 
been known for their primary function of inhibiting MMPs, it has now been widely recognized 
that TIMPs exhibit additional biological activities independent of their MMP inhibitory 
function. There are four TIMP members: TIMP-1, TIMP-2, TIMP-3 and TIMP-4, all of which 
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inhibit MMP activity. TIMP-1, -2 and -4 are secreted, whereas TIMP-3 is associated with the 
extracellular matrix. They are differentially regulated i.e. TIMP-1 expression is inducible, 
whereas TIMP-2 expression is constitutive (Gomez et al. 1997, Nagase et al. 1999). 
The MMP-independent activity of TIMPs includes promotion of cell growth as exhibited by 
TIMP-1 and TIMP-2, apoptosis, angiogenesis as well as a role in cell signaling. These roles of 
TIMPs surfaced when overexpression of these molecules gave conflicting results. There are 
several earlier studies showing an inhibitory role of TIMPs in tumor growth and metastasis; 
however, a number of studies have also demonstrated a tumor-promoting function and 
serum levels of TIMP correlated with poor prognosis as well (reviewed by Rojiani et al. 
2010).  
This paradoxical tumor promoting and tumor inhibiting role of TIMPs extends to gliomas as 
well. In the normal murine brain TIMP-2, -3 and -4 are strongly expressed whereas there is 
very little TIMP-1 expression (reviewed by Crocker et al. 2004) . Studies demonstrating the 
classical role of TIMP show, for example, that adding TIMP-2 to cultured glioblastoma cells 
reduces their invasion (Rao et al. 1994). Likewise, use of recombinant TIMP-1 on glioma cells 
showed reduced glioma invasion (VanMeter et al. 2001). Also, TIMP-1 was shown to cause 
significant reduction in brain metastasis of implanted fibrosarcoma cells (Kruger et al. 1998) 
and a decrease in TIMP-2 levels in glioblastomas has been noted as well (Lampert et al. 
1998). TIMP-3 overexpression suppresses glioma cell infiltration (Baker et al. 1999). 
Interestingly, TIMP-3 gene is one of the most highly methylated genes found in brain 
tumors (Esteller et al. 2001) and has been referred to as a tumor suppressor. 
Nakada et al. (Nakada et al. 2001) found that TIMP-1 but not TIMP-2 levels were 
significantly higher in glioblastoma multiforme compared to other glioma grades when 
using sandwich enzyme immunoassays. The same study developed stable transfectants of 
MT1-MMP and found that invasion and gelatinase activity of these transfectants could be 
totally inhibited by recombinant TIMP-2 but not recombinant TIMP-1. Lampert et al. 
(Lampert et al. 1998) have demonstrated a significant increase in TIMP-1 levels in 
glioblastomas compared to low grade tumors. Pagenstecher et al. (Pagenstecher et al. 2001) 
investigated the expression profiles of 9 MMPs and all TIMPs in different gliomas and 
found that TIMP-1 expression was the highest in GBMs and grade I gliomas with expression 
being confined to walls of neovessels. Groft et al. (Groft et al. 2001) carried out an extensive 
study looking at the expression and localization of all four TIMPs in normal human brains 
and gliomas. A detailed analysis of the expression of mRNA and protein levels showed that 
TIMP-2 and TIMP-3 expression pattern did not alter with tumor grade. However TIMP-1 
levels correlated positively with glioma malignancy, whereas TIMP-4 correlated negatively. 
TIMP-1 transcript expression was localized to tumor cell and the surrounding tumor 
vasculature while TIMP-4 transcripts were found mainly in tumor cells with minor 
expression seen in vessels. These authors also showed that in an in vitro assay, recombinant 
TIMP-4 reduced invasion of U251 glioma cells through Matrigel. Thus, although TIMPs 
have clearly been shown to play a significant role in the invasive and growth aspects of 
glioma, their precise roles remain elusive. However, TIMPs deserve further consideration in 
the search for targeted therapies. 
5. Therapeutic targeting of ECM molecules in glioma 
5.1 Targeting metalloproteinases  
MMPs play a crucial role in tumor growth, metastasis and angiogenesis and therefore have 
been the targets of antitumor therapy. Due to highly pleiotropic activities of MMPs the 
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outcomes of the clinical studies targeting these molecules have been disappointing, resulting 
often in increased tumor growth (reviewed by Rojiani et al. 2011). The initial use of broad 
spectrum MMP inhibitors interfering with the function of many of these enzymes in clinical 
trials had unforeseen consequences and resulted in early termination of these studies 
(reviewed by Coussens et al. 2002). These disappointing results led to the realization that the 
experimental data had to be reevaluated. For example, in animal studies the inhibitors were 
administered in early or intermediate stages of cancer whereas in humans they were 
administered in advanced stages. Besides, it has now been well documented that a number 
of MMPs play a protective role and their elimination can have adverse consequences 
(Martin and Matrisian 2007).  
However, given their significant contribution to tumor progression, MMPs still remain 
strong potential target candidates for therapeutic interventions. Therefore, it is not 
surprising that there are a number of MMP inhibitors (MMPI) in clinical trials (reviewed by 
Roy et al. 2009). Their effectiveness has yet to be proven. Also, the timing of delivery has 
been reconsidered since drugs given at earlier stages of cancer appear to be more effective 
than when given in advanced stages (Roy et al. 2009). 
Despite the adaptation of clinical trials and because of the pleiotropic activities of MMPs, a 
prediction of outcome is still difficult. Therefore, attention is now also given to other ECM 
molecules in the glioma microenvironment. New classes of targets need to be identified, eg. 
ECM molecules found within the cancer stem cell niche. Examples of other ECM targets are 
discussed below (sections 5.2, 6.1 and 6.2).  
5.2 Targeting HA and CD44 adhesion molecule  
We showed previously that blocking CD44 and interfering with HA-CD44 ligand-receptor 
interaction resulted in inhibition of glioma cell invasion, decreased HA production and led 
to glioma cell apoptosis (Wiranowska et al. 1998, Wiranowska et al. 2010). In addition, recent 
data by Xu et al. (Xu et al. 2010) showed that CD44 attenuates activation of the Hippo 
signaling pathway and that knockdown of CD44 expression resulted in the inhibition of 
glioblastoma. It was suggested that CD44 is a prime therapeutic target for treatment of 
glioblastoma (Xu et al. 2010). Therefore, further studies of this promising biological target 
molecule in glioma are warranted. The soluble recombinant CD44-HA-binding domain 
(CD44-HABD) inhibited proliferation of endothelial cells in vitro , blocked angiogenesis in 
vivo and inhibited growth of various tumors (Pall et al. 2004) providing hope for a new 
therapeutic approach to glioma. In addition, HA was recently used in vivo as a delivery 
carrier for chemotherapeutic paclitaxel (HA-paclitaxel) targeting CD44 positive ovarian 
carcinoma (Auzenne et al. 2007). Also, recently cisplatin carrying HA nanoparticles were 
evaluated as potential treatment for cancer (Jeong et al. 2008).  
6. Future therapies of glioma 
6.1 ECM therapeutic targets: Hopes and disappointments 
Current therapies like surgery, radiotherapy and chemotherapy are aimed at debulking of 
the brain tumor mass as well as targeting and eradicating proliferating tumor cells. 
However, these therapies do not address the quiescent population of the cancer stem cells. 
These cells, which are nourished and protected from therapeutic interventions by the 
microenvironment of the CSCs vascular niche can repopulate and initiate new tumor foci in 
the brain (Denysenko et al. 2010) 
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The modulation of the ECM microenvironment of the stem cell niche may be a promising 
approach especially in light of the finding that many of the genes and their products 
prognostic for the faith of proneural GBM were identified in the stroma of the brain tumor 
but not in the brain tumor cells themselves (as mentioned in Section 1: Holland 2011). 
Therapies targeting solely the brain tumors and their CSCs population may not be 
successful due to the high complexity and heterogeneity of brain tumors as demonstrated 
by the existence of various subtypes of GBMs. In addition, the genetic instability in 
expressing markers for undifferentiated cells within these tumors makes it difficult to assign 
the correct differentiation status of the tumor cells (Denysenko et al. 2010). Therefore, other 
therapeutic options should be pursued including therapies targeting the ECM of the CSCs 
vascular niches which would disrupt the microenvironment protective and supportive of 
the CSCs’ self-renewal.  
One of the stimulatory pro-angiogenic molecules released within the CSCs niche which 
enhances the survival of neural stem cells is VEGF (section 3.2). It has been shown that 
targeting VEGF and disruption of the niches by anti-VEGF treatment in vivo resulted in 
CSCs depletion and tumor growth inhibition (Calabrese et al. 2007). Some other studies 
however, showed that blocking VEGF in vivo resulted in growth of satellite tumors 
(Rubenstein et al. 2000). The early data obtained from clinical trials of GBM patients using 
VEGF-specific inhibitors such as bevacizumab combined with chemotherapeutic drug CPT-
11, showed promising results (Calabrese et al. 2007). However, recent finding by Ricci-
Vitiani et al. (Ricci-Vitiani et al. 2010) and Wang et al. (Wang et al. 2010) showed that newly 
formed blood vessels originating from the GBM stem cells that differentiated into 
endothelial cells were not responsive to anti-VEGF therapy (section 3.2). Most recently, it 
has been shown (di Tomaso et al. 2011) that patients treated with anti-VEGF therapy still 
contained Nestin + cells, a characteristic marker of the CSCs, despite a decreased 
vascularization of the brain tumors. The phase II results from anti-VEGF therapy in 
combination with chemotherapeutic CPT-11 failed to show prolonged survival of the GBM 
patients (Lai et al. 2011). Similar results were obtained from phase III clinical studies with 
recurrent GBM patients treated with cediranib, an inhibitor of VEGF alone or in 
combination with chemotherapeutic lomustine (Batchelor, 2010). In addition, it was shown 
recently by Takano et al. (Takano et al. 2010) that failure of bevacizumab treatment was 
associated with the high incidence of infiltrative tumors and MMP activity in the samples of 
urine. Therefore, based on the current state of knowledge, other approaches targeting ECM 
molecules of the vascular niche of CSCs need to be developed. 
6.2 Glioma possible new prognostic factors and new targets 
6.2.1 ECM prognostic factors  
There is evidence that some ECM molecules could serve as prognostic markers of anti-
angiogenic therapy of glioma indicative of the fate of the therapy. For example, Takano et al. 
(Takano et al. 2010) found that failure of bevacizumab (anti-VEGF antibody) treatment was 
associated with the high incidence of infiltrative tumors and levels of MMP activity in urine. 
Therefore, early detection and measurement of urine MMPs activity in samples from 
patients could be indicative of progressive disease. The detection of this biomarker could 
allow for earlier therapeutic intervention or alteration of a given anti-glioma therapy. 
Another ECM prognostic factor of potential therapeutic value could be presence of soluble 
collagen IV in the blood. It was shown by Sorensen et al. (Sorensen et al. 2009) that in 
patients treated with anti-angiogenic therapy using cediranib (pan-VEGF receptor tyrosine 
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kinase inhibitor) increased levels of collagen IV were found. This increase in circulating 
collagen IV was explained as the result of “blood vessels normalization” involving thinning 
of the abnormally thick tumor associated basement membrane of blood vessels. Increased 
levels of circulating collagen IV were associated with progression-free and overall patient 
survival.  
6.2.2 New ECM targets 
Recent data by Inoue et al. (Inoue et al. 2010) showed that cancer stem-like cells of GBM 
express MMP-13 responsible for invasion and migration of these cells suggesting that, 
MMP-13 might be a potential new therapeutic target for glioblastomas. Blocking VEGF or 
silencing VEGF receptor 2 inhibits the maturation of tumor endothelial progenitors into 
endothelium but does not stop the differentiation of CSCs (CD133+ cells) into endothelial 
cells. However, silencing of Notch (neural precursor receptor as mentioned in section 2.2) 
blocks the transition of CSCs (CD133+ cells) into endothelial progenitors (Wang et al. 2010). 
Therefore, Notch may be another potential new target in the stem cell niche. Fujita et al. 
(Fujita et al. 2011) showed that non-steroidal anti-inflammatory drugs (NSAID) such as Cox-
2 inhibitors suppressed gliomagenesis via inhibition of prostaglandin E2 mediated 
accumulation of myeloid derived suppressor cells. In addition, as mentioned earlier (section 
3.1) the Cox-2 inhibitor, celecoxib, inhibited in vitro microvascular channel formation 
associated with VEGF down regulation (Basu et al. 2005). The effect was more pronounced 
and prostaglandin E2-independent in a highly invasive breast cancer cell line when 
compared to a less invasive cell line. Based on these findings, it could be hypothesized that 
the NSAID class may have potential application in highly invasive glioma by targeting of 
the inflammatory molecules and immune cells as well as VM channel formation in the ECM. 
7. Summary and conclusions 
Despite years of research, glioma therapy remains a challenge due to very limited 
therapeutic options and short survival of glioma patients (as described in section 1). Until 
recently the focus of research evaluating possible target molecules for treatment was mainly 
on the cancer cell itself and its genetic characterization. Therefore, routine anti-glioma 
therapies such as chemotherapy or radiation are solely focused on targeting proliferating 
glioma cells by interfering with their cell cycle and resulting in glioma cell death. Very little 
attention was given to evaluation and validation of therapeutic targets in the extracellular 
matrix in glioma, its vasculature and brain stroma outside the tumor. Recent clinical trials 
targeting glioma vasculature with anti-angiogenic molecules initially provided encouraging 
results but later failed to be effective in slowing glioma progression. On the contrary, some 
of the anti-angiogenic treatments despite achieving blood vessel “normalization” within the 
tumor later resulted in the development of new glioma foci in the brain parenchyma away 
from the main lesion. It became known recently that a population of glioma CSCs present 
within the tumors was capable of escaping this anti-angiogenic therapy giving rise to tumor 
endothelium which had no markers for anti-angiogenic therapy.  
Another attempt to stop glioma cell invasion into the normal brain parenchyma involved 
targeting various MMPs responsible for remodeling ECM during glioma progression. 
Although there were high expectations, the results of these studies were disappointing 
again. It was found that many of the targeted MMPs had anti-tumor as well as tumorigenic 
activities and blocking or eliminating their activity lead to glioma regrowth. Clearly, the 
www.intechopen.com
 
Extracellular Matrix Microenvironment in Glioma Progression 
 
275 
ECM and the surrounding stroma play an essential role in glioma progression but more 
studies need to be done in order to find proper targets within the ECM to slow or inhibit 
glioma growth. This is supported by most recent finding by Holland (Holland 2011) that 
genes expressed in the microenvironment of the stroma rather than in the glioma itself may 
be predictive of glioma patient survival. This chapter provides a review of recent 
information relating to ECM targets for anti-glioma therapy. Consideration was given to 
various ECM molecules within the normal brain, in glioma and in the vascular niche 
harboring glioma stem cells. Consideration was also given to ECM rigidity and its effect on 
glioma progression. In addition to discussing some pertinent ECM molecules in glioma 
progression, also new emerging ECM targets and new prognostic markers candidates were 
discussed. All in all, ECM molecules are of great importance in the development of new 
therapeutic strategies and the information compiled in this chapter summarizing their role 
should be suitable to give guidance for the search and the development of new ECM anti-
glioma targets.  
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